Yu YC, Wang Y, He CL, Wang MR, Wang YM. Management of hepatitis C virus infection in hemodialysis patients. 1948-5182 2014; 6(6): 419-425 [PMID: 25018852 DOI: 10.4254/wjh.v6.i6.419]
Corresponding Author of This Article
Yue Wang, MD, PhD, Professor, National Institute for Viral Disease Control and Prevention, Chinese Center for Diseases Control and Prevention, Xicheng District, Yingxin Rd, Beijing 100052, China. euy-tokyo@umin.ac.jp
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
1948-5182. Jun 27, 2014; 6(6): 419-425 Published online Jun 27, 2014. doi: 10.4254/wjh.v6.i6.419
Management of hepatitis C virus infection in hemodialysis patients
Yue-Cheng Yu, Yue Wang, Chang-Lun He, Mao-Rong Wang, Yu-Ming Wang
Yue-Cheng Yu, Chang-Lun He, Mao-Rong Wang, Liver Diseases Center of PLA, the 81st Hospital of PLA, Nanjing University of Chinese Traditional Medicine, Nanjing 210002, Jiangsu Province, China
Yue Wang, National Institute for Viral Disease Control and Prevention, Chinese Center for Diseases Control and Prevention, Beijing 100052, China
Yu-Ming Wang, Institute of Infectious Diseases, Southwest Hospital, Third Military Medical University, Chongqing 400038, China
Author contributions: Yu YC and Wang Y collected the related references and wrote the first draft of the manuscript; He CL, Wang MR and Wang YM read through this paper and brought out several important opinions for revision.
Correspondence to: Yue Wang, MD, PhD, Professor, National Institute for Viral Disease Control and Prevention, Chinese Center for Diseases Control and Prevention, Xicheng District, Yingxin Rd, Beijing 100052, China. euy-tokyo@umin.ac.jp
Telephone: +86-10-63555751 Fax: +86-10-63510565
Received: November 5, 2013 Revised: April 3, 2014 Accepted: April 16, 2014 Published online: June 27, 2014 Processing time: 241 Days and 4.4 Hours
Core Tip
Core tip: The new hepatitis C virus (HCV) infections during maintenance hemodialysis (MHD) in recent years are mainly caused by the lack of stringent universal precautions. Strict implementation of universal precautions for HCV transmission has led to markedly decreased HCV infections in many hemodialysis units, but the anti-HCV negative HCV infection and occult HCV infection in MHD patients still should be noted. How to increase the sustained virological response and decrease the side effects is the key problem for the currently recommended interferon alpha-based antiviral therapy in MHD patients. Interferon alpha-free treatments with two or three direct-acting antivirals without ribavirin in MHD patients are waiting for future investigations.
